Poseida Therapeutics Total Revenue

Poseida Therapeutics (PSTX) currently reports a total revenue of $150M as of September 2024. That compares with $50M in the prior-year period — up 203.2% year over year. That is below the Healthcare sector average of $110B. Use the charts on this page to explore Poseida Therapeutics's total revenue history and peer comparisons.

Poseida Therapeutics's total revenue increased from $50M to $150M — a 203.2% year-over-year increase (period ending September 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Poseida Therapeutics's total revenue of $150M is lower than the Healthcare sector average of $110B. That is roughly 99.9% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Poseida Therapeutics reported $150M in total revenue as of September 2024. That compares with $50M in the prior-year period — up 203.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total revenue of $150M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $110B. From there, open related valuation or income-statement pages for Poseida Therapeutics, and consider following PSTX for alerts when major investors trade the stock.